Change in Biovitrum's Nomination Committee

After Investor AB's acquisition of shares in Biovitrum AB during
March, decision has been made regarding a change in the current
Nomination Committee. Charlotte Munthe Nilsson, Investor AB, has been
appointed new member of the Nomination Committee. Investor AB is the
largest shareholder in Biovitrum AB and represents according to the
announcement (March, 27th, 2009) 10,697,307 shares in Biovitrum,
which corresponds to 21.4 per cent of the share capital and 21.5 per
cent of the votes in the company.

With reference to the above the representative of Nordic Capital,
Henrik Lif, has left the Nomination Committee.

The Annual General Meeting will be held in Stockholm on 28 April
2009.




For further information please contact:

Martin Nicklasson, CEO
Phone: +46 8 697 25 45

Göran Arvidson, CFO
Cell phone: +46 70 633 30 42

Erik Kinnman, VP Investor Relations
Cell phone: +46 73 422 15 40
erik.kinnman@biovitrum.com


About Biovitrum
Biovitrum is a Swedish pharmaceutical company. The company markets  a
range  of  specialist  pharmaceuticals  internationally.  Using   its
expertise and experience  Biovitrum takes  scientific innovation  all
the way  to the  market and  to specialist  indication patients  with
significant medical  need. Research  expertise and  capabilities  are
focused on development and  production of biotechnology  therapeutics
within our prioritized  areas of hemophilia,  inflammation/autoimmune
diseases and malabsorption. The company has revenues of approximately
SEK 1.1 billion  and around 400  employees. It is  listed on the  OMX
Nordic  Exchange  in   Stockholm.  For  more   information  go  to
www.biovitrum.com.